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OBJECTIVEdThere is an established link between health-related functioning (HRF) and
cardiovascular disease (CVD) mortality, and it is known that those with diabetes predominantly
die of CVD. However, few studies have determined the combined impact of diabetes and im-
paired HRF on CVD mortality. We investigated whether this combination carries a higher CVD
risk than either component alone.
RESEARCHDESIGNANDMETHODSdThe Australian Diabetes, Obesity and Lifestyle
(AusDiab) study included 11,247 adults aged $25 years from 42 randomly selected areas of
Australia. At baseline (1999–2000), diabetes status was deﬁned using the World Health Orga-
nization criteria and HRF was assessed using the SF-36 questionnaire.
RESULTSdOverall, after 7.4 years of follow-up, 57 persons with diabetes and 105 without
diabetes had died from CVD. In individuals with and without diabetes, HRF measures were
signiﬁcant predictors of increased CVD mortality. The CVD mortality risks among those with
diabetes or impaired physical health component summary (PCS) alone were similar (diabetes
only: hazard ratio 1.4 [95% CI 0.7–2.7]; impaired PCS alone: 1.5 [1.0–2.4]), while those with
both diabetes and impaired PCS had a much higher CVD mortality (2.8 [1.6–4.7]) compared
with those without diabetes and normal PCS (after adjustment for multiple covariates). Similar
results were found for the mental health component summary.
CONCLUSIONSdThis study demonstrates that the combination of diabetes and impaired
HRF is associated with substantially higher CVDmortality. This suggests that, among those with
diabetes, impaired HRF is likely to be important in the identiﬁcation of individuals at increased
risk of CVD mortality.
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Cardiovascular disease (CVD) is theleading cause of mortality world-wide, accounting for .20% of all
deaths (1). Biological and behavioral var-
iables, such as diabetes, obesity, smoking,
and physical inactivity, are robust risk
factors for the development of CVD and
mortality (2). As well as these established
risk factors, subjective health status mark-
ers, such as health-related functioning
(HRF), have been shown to be associated
with an increased risk of cardiovascular
mortality (3). It has been shown that psy-
chosocial risk factors exert an association
similar in strength to that of biological
risk factors for CVD (4), and yet the two
types of risk factors are rarely assessed con-
currently.
HRF refers to how well an individual
functions in their daily life, physically and
socially, and their perceived physical and
mental well-being (5,6). Most of the liter-
ature to date examines HRF as an out-
come in patient populations, providing
an important indicator of the impact of
chronic disease (3,5,7). However, there
is increasing evidence to suggest that
poor HRF may predict the development
of disease, e.g., in type 2 diabetes (T2DM)
(8) and CVD (9). Because of the burden of
the daily management of T2DM and the
development of complications, HRF is
particularly important for people with
T2DM, with levels of health status shown
to be compromised in these populations
(5,7,10). Findings from previous studies
show that in samples of patients with
T2DM, persons reporting low levels of
HRF have higher risk of mortality com-
paredwith those reporting high functioning
(11,12). It is likely, therefore, that exposure
to T2DM and poor HRF has an additive, if
not synergistic, effect on the risk of cardio-
vascular mortality; however, the impact of
this combined relationship onmortality has
not been examined. It is important to un-
derstand whether the effects of each disor-
der simply have an additive impact or
whether their combined effects exert a syn-
ergistic effect (i.e., greater than the sum of
two independent effects) on mortality.
Using longitudinal data from a pop-
ulation-based, national study in Australia,
these analyses aimed to examine the com-





and response rates of the Australian Dia-
betes, Obesity and Lifestyle (AusDiab)
study have previously been described
(13). In brief, AusDiab was a popula-
tion-based study of 11,247 people aged
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$5 years from 42 randomly selected urban
and rural areas of Australia conducted in
1999–2000. At baseline, 55.3% (n =
11,247) of those completing a household
questionnaire undertook the full survey.
The study was approved by the ethics
committee of the International Diabetes
Institute. Informed consent for the study
was obtained from all participants.
Diabetes classiﬁcation was based on
plasma glucose results, using the 1999
World Health Organization diabetes clas-
siﬁcation (14). Diabetes was diagnosed
on the basis of fasting plasma glucose
(FPG) $7.0 mmol/L, 2-h plasma glucose
$11.1 mmol/L, or current treatment with
insulin or oral hypoglycemic medication.
For these analyses, complete data were
available on key variables of interest for
802 participants with T2DM and 9,177
without.
FPG and 2-h plasma glucose levels
were determined by a glucose oxidase
method using an Olympus AU600 auto-
mated analyzer (Olympus Optical, Tokyo,
Japan). Serum triglycerides, total choles-
terol, and HDL cholesterol were measured
by enzymatic methods. Total HbA1c analy-
sis was performed using high-performance
liquid chromatography (Bio-Rad Variant
Haemoglobin Testing System; Bio-Rad,
Hercules, CA) with standardized con-
version to HbA1c values (normal range
4.2–6.3%). Blood pressure was measured
using Dinamap or a standard mercury
sphygmomanometer. To account for any
effect due to differential measurement er-
ror, we adjusted manual blood pressure
measurements as previously described
(15). Hypertension was deﬁned as pres-
ent if systolic blood pressure (SBP) was
$140 mmHg and diastolic blood pressure
$90 mmHg or if the participant reported
current treatment for hypertension. Height
and weight weremeasured in light clothing
by a trained observer. BMI was calculated
as weight in kilograms divided by the
square of height in meters. Information
on smoking, medication, and history of di-
abetes was obtained by interview.
Mortality status and underlying and
contributory causes of death were deter-
mined by linking the AusDiab cohort to
the AustralianNational Death Index (NDI).
Name, sex, date of birth, state, date of last
contact, and date of death (if available)
were used to match participants to the
NDI. The accuracy of the NDI to ascertain
CVD deaths and vital status has previously
been established (16). Only high-level
matches were accepted as conﬁrmed
deaths, and wherever possible, deaths
were conﬁrmed by direct communication
with the decedent’s family. People who
were not matched to the NDI were as-
sumed to be alive. Deaths were attributed
to CVD if the underlying cause of death
was coded I10-I25, I46.1, I48, I50-I99, or
R96 according to the 2006 ICD-10. In ad-
dition, participants with uncomplicated
diabetes (ICD-10 codes E109, E119, or
E149) or unspeciﬁed hyperlipidemia
(ICD-10 code E785) as an underlying
cause of death on the death certiﬁcate
were attributed a CVD death (n = 4) if
any of the CVD codes (I10-I25, I46.1,
I48, I50-I99, or R96) were recorded in
the ﬁrst position on the death certiﬁcate.
Health-related functioning was as-
sessed using version 1 of the SF-36 Health
Survey (6). The SF-36 (http://www.sf-36.
org/tools/sf36.shtml) is a self-administered
measure of perceived health status over
the preceding week, comprising eight do-
mains: physical functioning, role-physical,
bodily pain, general health, vitality, social
functioning, role-emotional, and mental
health. Items for each dimension were
coded, summed, and translated from
worst health (0) to best health (100). Phys-
ical functioning refers to the ability to per-
form activities (walking, climbing stairs,
bending and stretching, and lifting and
carrying objects) without limitation. Role
limitation (physical) refers to the limita-
tions that reduced physical health has on
the range and extent of physical activities
one is able to perform. Bodily pain refers
to the severity of pain and its impact on
daily activities. General health is a rating
of one’s own health, a comparison with
others’ health, and proneness to illness.
Vitality refers to how energetic or tired a
person feels. Social functioning refers to
the impact of physical and emotional
health on the ability to perform normal
social activities. Role limitation (emo-
tional) refers to limitations that emotional
problems put on the range and extent of
activities one can perform. Mental health
refers to the degree of nervousness or
calmness and happiness or sadness.
In addition, the survey established
scores for two summary measures: phys-
ical health component summary (PCS)
and mental health component summary
(MCS) scores. Both PCS and MCS are
dimensions of health status that have
been shown to be useful and valid meas-
ures of mental and physical health func-
tioning relative to health proﬁle. Overall,
the SF-36 has been widely used in studies
of chronic disease in both patient (6) and
general population (17) samples.
Statistical methods
Statistical analysis was performed using
STATA, version 11.0, for Windows
(STATA, College Station, TX). Descrip-
tive information for each of the variables
was derived and distribution assessed.
The lowest quartile (i.e., poor health-
related functioning) of each dimension of
the SF-36 scale was used to deﬁne im-
paired HRF (thresholds: PCS #70 and
MCS #68). Categorical variables de-
scribing the pattern of mortality by the
SF-36 summary scales were created.
The categories were as follows (partici-
pant numbers given for PCS and MCS,
respectively): 1) no T2DM and normal
PCS or MCS (n = 7,098 and 6,640),
2) T2DM and normal PCS or MCS (n =
444 and 500), 3) no T2DM and impaired
PCS or MCS (n = 2,079 and 2,178), and
4) T2DM and impaired PCS or MCS (n =
358 and 179).
Univariate associations between each
dimension of the SF-36 scale and other
variables of interest were assessed using
ANOVA for metric variables and a x2 test
for categorical variables. Multivariate
analysis was performed using Cox pro-
portional hazards models. The ﬁrst model
was adjusted for age and sex. Model 2
adjusted for age, sex, BMI, smoking, his-
tory of CVD, SBP, lipid therapy, total cho-
lesterol, and triglycerides. Another model
(Model 3) tested the interaction between
each domain of SF-36 andHbA1c to assess
the synergistic effects of T2DM and im-
paired HRF on mortality beyond the ad-
ditive effects of each condition. It should
be noted that some of the eight domains
were too highly correlated to be included
in the same model in order to test their
independence from one another. There-
fore, these results should not be interpreted
as independent of the other domains.
RESULTSdOverall, after 7.4 years of
follow-up, 57 of those with T2DM and
105 without had died of CVD. Of these,
66% were male. Complete data for these
analyses were available on 9,979 study
participants. Table 1 displays the baseline
sample characteristics. Themean (SD) age
of those without T2DM was 51 years (14)
and with T2DM was 62 years (13). Six-
teen percent of those without T2DM and
14% of those with T2DM were current
smokers. Overall, 7% of those without
T2DM and 22% of those with T2DM at
baseline had a history of CVD. For each
dimension of the SF-36, people with
T2DM had lower scores compared with
people without T2DM.
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The hazard ratios (HRs) (95% CI) for
CVD and all-cause mortality according to
domains of HRF and HbA1c are shown in
Table 2. Low levels of physical functioning,
general health perception, and vitality
were associated with higher CVD mortal-
ity (adjusted for age and sex). This associ-
ation was only partially attenuated by
further adjustment for BMI, smoking,
history of CVD, SBP, lipid therapy, total
cholesterol, and triglycerides. Low levels
of physical functioning, role limitation
(physical), bodily pain, general health per-
ception, vitality, social functioning, and
role limitation (emotional) were associ-
ated with higher all-cause mortality (after
controlling for age and sex). Further ad-
justment for BMI, smoking, history of
CVD, SBP, lipid therapy, total cholesterol,
and triglycerides had little impact on the
elevated HRs of these domains on all-
cause mortality. As stated previously,
due to strong correlation between cer-
tain domains, it was not possible to iden-
tify whether the impact of each domain
was independent of the effects of the
other domains.
The unadjusted combined survival
for CVD mortality by categories of
T2DM and physical and mental health–
related functioning is outlined in Fig. 1.
The HRs (95% CI) for all-cause and CVD
mortality according to categories of HRF
and diabetes status are shown in Table 3.
The HRs for CVD mortality among those
with T2DM or impaired PCS alone were
similar, while those with both T2DM and
impaired PCS had a much higher CVD
mortality (T2DM only 1.4 [95% CI 0.7–
2.7], impaired PCS alone 1.5 [1.0–2.4],
and both T2DM and impaired PCS 2.8
[1.6–4.7]) compared with the persons
without T2DM and with normal PCS (af-
ter adjustment for age, sex, BMI, smoking,
history of CVD, SBP, lipid therapy, total
Table 1dBaseline characteristics of the AusDiab population
All No diabetes Diabetes
Population characteristics
n* 9,979 9,177 802
Age (years) 51 (14) 50 (14) 62 (13)
Sex (% male) 45 45 53
FPG (mmol/L) 5.6 (1.2) 5.4 (0.5) 8.1 (2.8)
BMI (kg/m2) 27.0 (5.0) 26.7 (4.8) 30.0 (6.1)
Lipid treatment 8 7 25
Total cholesterol (mmol/L) 5.6 (1.1) 5.6 (1.1) 5.7 (1.1)
Triglycerides (mmol/L) 1.3 (0.9–1.8) 1.2 (0.9–1.8) 1.9 (1.3–2.8)
Current smoker 16 16 14
Hypertension 32 29 70
SBP (mmHg) 129 (19) 128 (18) 144 (20)
Diastolic blood pressure (mmHg) 70 (12) 70 (12) 75 (12)
History of CVD† 8 7 22
HRF measures
Physical functioning 81.8 (20.8) 83.0 (19.8) 67.2 (25.9)
Role limitation: physical 79.8 (34.5) 81.0 (33.6) 65.8 (40.9)
Bodily pain 74.0 (23.1) 75.0 (22.8) 68.1 (25.8)
General health perception 69.9 (19.1) 70.8 (18.6) 60.3 (21.1)
Vitality 62.1 (20.2) 62.5 (20.1) 57.9 (21.4)
Social functioning 86.5 (20.5) 86.8 (20.2) 82.5 (23.4)
Role limitation: emotional 83.2 (31.8) 83.8 (31) 77.2 (36.4)
Mental health 75.9 (16.8) 75.9 (16.7) 75.6 (16.9)
HRF summary scores
MCS score (%) 51.0 (9.8) 51.0 (9.8) 51.4 (9.8)
PCS score (%) 50.5 (10.5) 51.0 (10.0) 44.2 (12.9)
Data are means (SD) or percentages unless otherwise indicated. Triglyceride values are presented as medians
and interquartile ranges. *Only those with complete data on variables modeled are included. †History of
stroke, angina, or heart attack.
Table 2dHRs (95% CI) for all-cause and CVD mortality according to dimensions of HRF and HbA1c
CVD mortality risk All-cause mortality risk
Age and sex adjustment Multivariate adjustment* Age and sex adjustment Multivariate adjustment*
Physical functioning† 0.84 (0.79–0.90) 0.85 (0.79–0.91) 0.84 (0.81–0.87) 0.84 (0.81–0.88)
HbA1c 1.19 (1.03–1.37) 1.19 (1.01–1.38) 1.11 (1.01–1.22) 1.11 (1.01–1.22)
Role limitation: physical† 0.97 (0.93–1.01) 0.98 (0.94–1.03) 0.94 (0.92–0.96) 0.95 (0.93–0.97)
HbA1c 1.20 (1.06–1.37) 1.17 (1.01–1.37) 1.13 (1.03–1.23) 1.10 (1.00–1.21)
Bodily pain† 0.96 (0.90–1.03) 0.98 (0.91–1.05) 0.94 (0.91–0.98) 0.96 (0.92–0.99)
HbA1c 1.21 (1.06–1.37) 1.18 (1.01–1.37) 1.15 (1.05–1.25) 1.12 (1.02–1.23)
General health perception† 0.85 (0.78–0.93) 0.89 (0.81–0.97) 0.83 (0.80–0.87) 0.86 (0.82–0.90)
HbA1c 1.17 (1.02–1.34) 1.16 (0.99–1.34) 1.10 (1.00–1.20) 1.01 (0.99–1.20)
Vitality† 0.92 (0.84–0.99) 0.95 (0.88–1.04) 0.89 (0.85–0.93) 0.92 (0.88–0.96)
HbA1c 1.20 (1.05–1.36) 1.17 (1.01–1.36) 1.13 (1.03–1.23) 1.11 (1.01–1.21)
Social functioning† 0.95 (0.88–1.01) 0.98 (0.91–1.05) 0.91 (0.88–0.94) 0.93 (0.90–0.96)
HbA1c 1.20 (1.06–1.37) 1.18 (1.01–1.37) 1.14 (1.04–1.24) 1.11 (1.01–1.22)
Role limitation: emotional† 0.97 (0.93–1.02) 0.99 (0.94–1.03) 0.97 (0.95–0.99) 0.99 (0.96–1.01)
HbA1c 1.20 (1.06–1.36) 1.17 (1.01–1.36) 1.14 (1.05–1.24) 1.11 (1.01–1.22)
Mental health† 0.99 (0.90–1.11) 1.04 (0.93–1.15) 0.95 (0.91–1.01) 0.99 (0.94–1.04)
HbA1c 1.20 (1.06–1.36) 1.18 (1.01–1.36) 1.14 (1.05–1.24) 1.11 (1.01–1.22)
*Only those with complete data on variables modeled are included. Model 1 adjusted for age and sex. Model 2 adjusted for age, sex, BMI, smoking, history of CVD,
SBP, lipid therapy, total cholesterol, and triglycerides. †Per 10-point change. Please note that individual domain results are not independent of other domain effects.
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cholesterol, and triglycerides). Adjust-
ment for MCS (Model 3) did not appre-
ciably affect the impact of PCS, either
alone or in combination with T2DM, on
all-cause or CVD mortality. For MCS, the
HR for CVD mortality among those with
T2DMonly was 1.4 (95%CI 0.9–2.1) and
for impaired MCS alone was 0.7 (0.4–1.3),
while the HR for CVD mortality in people
with both T2DMand impairedMCSwas 2.3
(1.2–4.1). Inclusion of PCS in Model 3 did
not substantially affect these results; the
individual impact of MCS and its combined
impact with diabetes on mortality were in-
dependent of PCS.
To test the nature of the relationship
between diabetes and HRF on mortality,
i.e., whether effects of the combined disor-
ders on mortality were additive or syner-
gistic, interactionswere tested between each
domain of the SF-36 andHbA1c, andwhere
signiﬁcant, these terms were added to the
ﬁnal model for each dimension. For CVD
mortality, there was a signiﬁcant interaction
between bodily pain andHbA1c (P=0.015).
For all-cause mortality, there were signiﬁ-
cant interactions between physical func-
tioning and HbA1c (P = 0.035) and
between bodily pain and HbA1c (P =
0.033). There was no signiﬁcant interaction
between HbA1c and mental HRF.
CONCLUSIONSdThis is the ﬁrst
study to show that the combined expo-
sure to type 2 diabetes and impaired HRF
is associated with an increased risk of
cardiovascular and all-cause mortality.
Physical and mental health functioning
both demonstrated this additive relation-
ship with diabetes on increased mortality,
and T2DM and components of impaired
physical HRF (the domains of bodily pain
and physical functioning) showed a syn-
ergistic impact on mortality. These in-
teraction results indicated that greater
bodily pain and poorer physical function-
ing were more strongly related to mortal-
ity among people with higher HbA1c
compared with those with lower HbA1c.
This may suggest that people with dia-
betes who experience high levels of pain
or impaired physical functioning are less
likely to participate in behaviors that
could improve glycemic control and re-
duce the development of complications,
therefore increasing their mortality risk. It
is also possible that these speciﬁc HRF
impairments are markers of other pro-
cesses that might increase mortality risk.
Owing to strong correlations between
certain HRF domains, it was not possible
to identify whether bodily pain and phys-
ical functioning exerted effects on mor-
tality independent of one another or
independent of other domains of HRF.
Previous research in T2DM has
largely focused on assessing and modify-
ing conventional risk factors, such as
lowering blood glucose and lipids, and
increasing physical activity. This ap-
proach does not, however, look beyond
clinical parameters and fails to take into
account the role of subjective health
status markers, which can reﬂect other
physical and psychological symptom bur-
den as well as the individual’s perception
of their health (5). A number of studies
have now begun to recognize and advo-
cate the use of HRF measures in risk as-
sessment and stratiﬁcation for CVD (3,9)
and diabetes (11).
Our ﬁndings indicate that HRF is
related to life expectancy and that among
people with T2DM, impaired HRF signif-
icantly increases CVD and all-cause mor-
tality. In populationswith type 2 diabetes, a
Figure 1dA: Unadjusted survival for CVD mortality according to diabetes and PCS score cat-
egories: the AusDiab study. B: Unadjusted survival for CVD mortality according to diabetes and
MCS score categories: the AusDiab study.
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few studies have shown an independent
inverse relationship between HRF and all-
cause and cardiovascular mortality, using
both the SF-36 and the EuroQoL (EQ-5D)
scales (11,12). Both instruments are ge-
neric measures of HRF widely used among
patient samples (12) and the general pop-
ulation (17). The EQ-5D, developed by the
EuroQol group, measures an individual’s
health state throughﬁve dimensions:mobil-
ity, self-care, usual activity, pain/discomfort,
anxiety, and depression (18). Previous
studies have not been able to demonstrate
the combined impact of T2DM and im-
pairedHRFonmortality because their sam-
ples included only people with diabetes
(11,12). Research has shown that people
with T2DM are more likely to experience
impaired HRF compared with populations
without diabetes (5,7,10). It is also well es-
tablished that hyperglycemia promotes
CVD risk through various mechanisms, in-
cluding inﬂammation and endothelial dys-
function (19), which consequently increase
atherosclerosis and plaque rupture. There-
fore, our ﬁndings support previous work
demonstrating separate associations be-
tween HRF and T2DM and between
T2DM and mortality. Furthermore, this
study extends existing literature, provid-
ing data indicating the synergistic impact
of T2DM and impaired HRF on mortal-
ity, and highlights the signiﬁcance of
HRF as a CVD risk factor by showing
that those with impaired HRF without
diabetes have a risk of CVD mortality
similar to that of people with normal
HRF and diabetes.
We have shown that both the physical
and mental components of HRF indepen-
dently contribute to the risk of mortality.
This supports previous research from a
community sample in Taiwan, which
demonstrated a relationship between
both the physical andmental components
of HRF and mortality, even after adjust-
ment for a range of covariates (20). How-
ever, a number of studies have failed to
ﬁnd an association betweenMCS andmor-
tality. In the Ziprasidone Observational
Study of Cardiac Outcomes (ZODIAC),
physical but not mental health function-
ing was related to mortality in partici-
pants with T2DM (11), and a similar
ﬁnding was shown in a cardiac patient
sample (3). Despite T2DM and impaired
MCS signiﬁcantly increasing mortality in
this study, our results indicate that the
physical component of HRF did have a
stronger effect onmortality than themen-
tal component.
The SF-36 incorporates an assess-
ment of self-rated health, for which there
is signiﬁcant literature supporting its role
as a predictor of mortality (21). Self-rated
health provides an overall evaluation of
current mental and physical health, as
well as the trajectory of health. Explana-
tions for the strength of this relationship
suggest that self-rated health may inﬂu-
ence behaviors that will affect future
health but also that such subjective meas-
ures are more inclusive and accurate
measurements of health than individual
clinical variables (22).
There is strong evidence to suggest
that diabetes and HRF are associated with
psychosocial risk factors, such as depres-
sion (7,23). In a sample of patients with
T2DM, both the PCS and MCS of SF-36
were associated with depression, anxiety,
and illness perceptions (24). Therefore,
T2DM and impaired HRF may promote
psychosocial ill health, demonstrating a
pathway through which CVD mortality
risk may be elevated. The mediating effect
of psychosocial adversity may act directly
on physiological processes that promote
CVD risk. For example, a psychological
intervention for cancer sufferers showed
that, by improving depressive symptoms,
inﬂammatorymarkers were reduced (25).
Another mechanism through which the
cumulative effects of T2DM and impaired
HRF increase mortality may be through
behaviors like poor diet, diabetes self-
care, and medical adherence (23). There
is a clear link between behaviors such as
diet and exercise and HRF (5); however,
the literature is more limited regarding
the self-management behaviors of adher-
ence and compliance to medical routines.
Hanestad and Albrektsen (26) showed
that, in a sample of patients with type 1
diabetes, HRF was associated with greater
perceived ease of regimen adherence. Re-
sults from another cross-sectional study
indicated that higher HRF was related to
good compliance (27). Therefore, amelio-
rating HRF levels through psychological
and behavioral interventions may beneﬁt
health outcomes by improving psycho-
logical health and health care practices
of individuals with T2DM.
There are limitations to be consid-
ered. There is some debate about the use
of SF-36 as ameasurement tool for quality
of life among people with diabetes (28);




Model 1 Model 2* Model 3*
PCS score
All-cause mortality
No T2DM and normal PCS 170 (2.4) 1.0 1.0 1.0
T2DM and normal PCS 32 (7.2) 1.3 (0.9–1.8) 1.2 (0.8–1.8) 1.2 (0.8–1.8)
No T2DM and impaired PCS 189 (9.1) 1.8 (1.4–2.2) 1.6 (1.3–2.0) 1.7 (1.3–2.1)
T2DM and impaired PCS 91 (25.4) 3.3 (2.5–4.3) 2.8 (2.1–3.7) 2.9 (2.1–3.9)
CVD mortality
No T2DM and normal PCS 38 (0.5) 1.0 1.0 1.0
T2DM and normal PCS 11 (2.5) 1.6 (0.8–3.1) 1.4 (0.7–2.7) 1.4 (0.7–2.7)
No T2DM and impaired PCS 53 (2.6) 1.7 (1.1–2.6) 1.5 (1.0–2.4) 1.6 (1.0–2.6)
T2DM and impaired PCS 32 (8.9) 3.6 (2.2–5.9) 2.8 (1.6–4.7) 2.9 (1.7–5.0)
MCS score
All-cause mortality
No T2DM and normal MCS 276 (4.0) 1.0 1.0 1.0
T2DM and normal MCS 86 (14.7) 1.6 (1.3–2.1) 1.5 (1.1–1.9) 1.4 (1.1–1.8)
No T2DM and impaired MCS 83 (3.7) 1.2 (0.9–1.5) 1.0 (0.8–1.3) 0.8 (0.6–1.1)
T2DM and impaired MCS 37 (17.1) 2.3 (1.6–3.2) 1.8 (1.3–2.6) 1.5 (1.0–2.1)
CVD mortality
No T2DM and normal MCS 75 (1.1) 1.0 1.0 1.0
T2DM and normal MCS 29 (5.0) 1.7 (1.1–2.6) 1.4 (0.9–2.1) 1.3 (0.8–2.1)
No T2DM and impaired MCS 16 (0.7) 0.8 (0.5–1.4) 0.7 (0.4–1.3) 0.6 (0.3–1.0)
T2DM and impaired MCS 14 (6.5) 2.8 (1.6–5.0) 2.3 (1.2–4.1) 1.8 (1.0–3.3)
Data are HR (95% CI) or n (%). *Only those with complete data on variables modeled are included. Model 1
adjusted for age and sex. Model 2 adjusted for age, sex, BMI, smoking, history of CVD, SBP, lipid therapy,
total cholesterol, and triglycerides. Model 3 included additional adjustment for the MCS score for the PCS
score results and additional adjustment for the PCS score for the MCS score.
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however, it is generally accepted that, in
population samples, it accurately assesses
health status or HRF (17). It is possible
that impaired HRF may reﬂect some un-
measured variables; therefore, some of the
variance attributed to impaired HRF may
be explained by other factors. Complica-
tions relating to diabetes are likely to ex-
plain some of the increased mortality
observed among people with diabetes. Al-
though complete data on all diabetes-
related complications were not available,
the inclusion of albumin-to-creatinine ratio
as a covariate did not appreciably affect the
ﬁndings (i.e., PCS remained a signiﬁcant
independent predictor of mortality, and
the combination of both summary compo-
nents of HRF with T2DM signiﬁcantly in-
creased the risk of mortality). Data on
depression were not available to explore
its role as a mediating variable. The mod-
erate response rates at baseline mean that
theﬁndingsmay be subject to response and
selection biases and therefore may not be
generalizable across all populations. How-
ever, the large national sample and quality
of the glucose tolerance data give this work
considerable weight.
This study demonstrates the combined
impact of diabetes and impaired HRF on
cardiovascular and all-cause mortality.
These ﬁndings indicate that, among people
with T2DM, impaired HRF is likely to be
important in the identiﬁcation of individ-
uals at increased risk of CVD mortality.
AcknowledgmentsdE.D.W. is supported by
a Diabetes UK Fellowship (09/0003833). J.E.S.
is supported by a National Health andMedical
Research Council Fellowship (586623). R.J.T.
is supported by the Lions Foundation. The
AusDiab study, cocoordinated by the Baker
IDI Heart and Diabetes Institute, was supported
in part by the Victorian Government’s Opera-
tional Infrastructure Support Program, the Na-
tional Health and Medical Research Council
(NHMRC Grant 233200), the Australian Gov-
ernment Department of Health and Ageing, City
Health Centre–Diabetes Service–Canberra, the
Department ofHealth andCommunity Services–
Northern Territory, the Department of Health
andHuman Services–Tasmania, the Department
of Health–New South Wales, the Department
of Health–Western Australia, the Department of
Health–South Australia, the Department of
Human Services–Victoria, Diabetes Australia,
Diabetes Australia Northern Territory, Estate of
the Late Edward Wilson, the Jack Brockhoff
Foundation, Kidney Health Australia, Marian&
FH Flack Trust, Menzies Research Institute, and
the Pratt Foundation.
The AusDiab study was also supported by
Abbott Australasia Pty Ltd, AlphapharmPty Ltd,
AstraZeneca, Bristol-Myers Squibb, Eli Lilly
Australia, GlaxoSmithKline, Janssen-Cilag,
Merck Sharp & Dohme, Novartis Pharmaceut-
icals, Novo Nordisk Pharmaceuticals, Pﬁzer
Pty Ltd, Queensland Health, Roche Diagnostics
Australia, Royal Prince Alfred Hospital (Sydney,
NewSouthWales, Australia), sanoﬁ-aventis, and
Sanoﬁ-Synthelabo. No other potential conﬂicts
of interest relevant to this article were reported.
E.D.W. wrote the manuscript. L.R. con-
tributed to the analyses and reviewed and
edited the manuscript. B.F.O. and C.R. re-
viewed and edited the manuscript. J.E.S. con-
tributed to discussion and reviewed and edited
the manuscript. R.J.T. contributed to discus-
sion, analyses, and manuscript writing and re-
viewed and edited the manuscript. E.D.W. and
R.J.T. are the guarantors of this work and, as
such, had full access to all the data in the study
and take responsibility for the integrity of the
data and the accuracy of the data analysis.
Parts of this study were presented in ab-
stract form at the 70th Scientiﬁc Sessions of
the American Diabetes Association, Orlando,
Florida, 25–29 June 2011.
The authors are enormously grateful for the
invaluable contribution to the set-up and ﬁeld
activities of AusDiab, to the Baker IDI Heart
and Diabetes Institute staff at the time of data
collection: B. Atkins (also of Monash Medical
Centre), A. Bonney, M. Dalton, M. de Courten
(nowofUniversity ofCopenhagen),D.Dunstan,
H. Jahangir, A. Meehan, N. Meinig, S. Murray,
A. Stewart, R. Tapp (now of National Vision
Research Institute), T. Whalen, F. Wilson, and
P. Zimmet, as well as A. Allman and C. Reid
(HITECH Pathology), S. Bennett (Australian
Institute of Health & Welfare), S. Chadban
(University of Sydney), T. Dwyer (Menzies
Centre for Population Research), D. Jolley
(Monash University), D. McCarty (Centre for
Eye Research Australia), K. O’Dea (Menzies
School of Health Research), K. Polkinghorne
(Monash Medical Centre), P. Phillips (Queen
Elizabeth Hospital), and H. Taylor (Centre for
Eye Research Australia).
References
1. World Health Organization. The Global
Burden of Disease: 2004 Update. Geneva,
World Health Organization, 2008
2. Barr EL, Zimmet PZ, Welborn TA, et al.
Risk of cardiovascular and all-cause mor-
tality in individuals with diabetesmellitus,
impaired fasting glucose, and impaired
glucose tolerance: the Australian Diabetes,
Obesity, and Lifestyle Study (AusDiab).
Circulation 2007;116:151–157
3. Rumsfeld JS, MaWhinney S, McCarthy M
Jr, et al. Health-related quality of life as a
predictor of mortality following coronary
artery bypass graft surgery. Participants
of the Department of Veterans Affairs
Cooperative Study Group on Processes,
Structures, and Outcomes of Care in
Cardiac Surgery. JAMA 1999;281:1298–
1303
4. Rosengren A, Hawken S, Ôunpuu S, et al.;
INTERHEART investigators. Association
of psychosocial risk factors with risk of
acute myocardial infarction in 11119 ca-
ses and 13648 controls from 52 countries
(the INTERHEART study): case-control
study. Lancet 2004;364:953–962
5. Rubin RR, Peyrot M. Quality of life and
diabetes. Diabetes Metab Res Rev 1999;
15:205–218
6. Ware JE Jr, Sherbourne CD. The MOS
36-item short-form health survey (SF-36).
I. Conceptual framework and item selec-
tion. Med Care 1992;30:473–483
7. Wexler DJ, Grant RW,Wittenberg E, et al.
Correlates of health-related quality of life
in type 2 diabetes. Diabetologia 2006;49:
1489–1497
8. Tapp RJ, O’Neil A, Shaw JE, Zimmet PZ,
Oldenburg BF; AusDiab Study Group. Is
there a link between components of
health-related functioning and incident
impaired glucose metabolism and type 2
diabetes? The Australian Diabetes Obesity
and Lifestyle (AusDiab) study. Diabetes
Care 2010;33:757–762
9. Spertus JA, Jones P, McDonell M, Fan V,
Fihn SD. Health status predicts long-term
outcome in outpatients with coronary
disease. Circulation 2002;106:43–49
10. Al-Shehri AH, Taha AZ, Bahnassy AA,
Salah M. Health-related quality of life in
type 2 diabetic patients. Ann Saudi Med
2008;28:352–360
11. Kleefstra N, Landman GW, Houweling
ST, et al. Prediction of mortality in type 2
diabetes from health-related quality of life
(ZODIAC-4). Diabetes Care 2008;31:932–
933
12. Landman GW, van Hateren KJ, Kleefstra N,
Groenier KH, Gans RO, Bilo HJ. Health-
related quality of life and mortality in a
general and elderly population of patients
with type 2 diabetes (ZODIAC-18). Di-
abetes Care 2010;33:2378–2382
13. Dunstan DW, Zimmet PZ, Welborn TA,
et al.; Australian Diabetes, Obesity and
Lifestyle Study (AusDiab). The Australian
Diabetes, Obesity and Lifestyle Study
(AusDiab)dmethods and response rates.
Diabetes Res Clin Pract 2002;57:119–129
14. World Health Organization. Deﬁnition,
Diagnosis and Classiﬁcation of Diabetes
Mellitus and Its Complications. Part 1. Di-
agnosis and Classiﬁcation of Diabetes Mel-
litus.Geneva,World Health Organization,
1999
15. Briganti EM, Shaw JE, Chadban SJ, et al.;
Australian Diabetes, Obesity and Lifestyle
Study (AusDiab). Untreated hypertension
among Australian adults: the 1999-2000
Australian Diabetes, Obesity and Lifestyle
Study (AusDiab). Med J Aust 2003;179:
135–139
16. Magliano D, Liew D, Pater H, et al. Ac-
curacy of the Australian National Death
Index: comparison with adjudicated fatal
outcomes among Australian participants
1072 DIABETES CARE, VOLUME 35, MAY 2012 care.diabetesjournals.org
Diabetes, health-related functioning, and mortality
in the Long-term Intervention with Pra-
vastatin in Ischaemic Disease (LIPID)
study. Aust N Z J Public Health 2003;27:
649–653
17. Jenkinson C, Wright L, Coulter A. Crite-
rion validity and reliability of the SF-36
in a population sample. Qual Life Res
1994;3:7–12
18. EuroQol G. EuroQolda new facility for
the measurement of health-related quality
of life. The EuroQol Group. Health Policy
1990;16:199–208
19. Van Gaal LF, Mertens IL, De Block CE.
Mechanisms linking obesity with cardio-
vascular disease. Nature 2006;444:875–
880
20. Tsai SY, Chi LY, Lee CH, Chou P. Health-
related quality of life as a predictor of
mortality among community-dwelling older
persons. Eur J Epidemiol 2007;22:19–26
21. JylhäM.What is self-rated health and why
does it predict mortality? Towards a uni-
ﬁed conceptual model. Soc Sci Med 2009;
69:307–316
22. Idler EL, Benyamini Y. Self-rated health
and mortality: a review of twenty-seven
community studies. J Health Soc Behav
1997;38:21–37
23. Goldney RD, Phillips PJ, Fisher LJ, Wilson
DH. Diabetes, depression, and quality of
life: a population study. Diabetes Care
2004;27:1066–1070
24. Paschalides C, Wearden AJ, Dunkerley R,
Bundy C, Davies R, Dickens CM. The
associations of anxiety, depression and
personal illness representations with gly-
caemic control and health-related quality
of life in patients with type 2 diabetes
mellitus. J Psychosom Res 2004;57:557–
564
25. Thornton LM, Andersen BL, Schuler
TA, Carson WE 3rd. A psychological
intervention reduces inﬂammatorymarkers
by alleviating depressive symptoms:
secondary analysis of a randomized
controlled trial. Psychosom Med 2009;71:
715–724
26. Hanestad BR, Albrektsen G. Quality of
life, perceived difﬁculties in adherence
to a diabetes regimen, and blood glucose
control. Diabet Med 1991;8:759–764
27. Chaveepojnkamjorn W, Pichainarong N,
Schelp FP, Mahaweerawat U. Quality of
life and compliance among type 2 diabetic
patients. Southeast Asian J Trop Med
Public Health 2008;39:328–334
28. Speight J, ReaneyMD, Barnard KD. Not all
roads lead to Rome-a review of quality of
life measurement in adults with diabetes.
Diabet Med 2009;26:315–327
care.diabetesjournals.org DIABETES CARE, VOLUME 35, MAY 2012 1073
Williams and Associates
